How many hours does brigatinib last?

The efficacy of brigatinib is not measured in hours, but rather in terms of its effect and duration of treatment of the disease. Brigatinib is an oral targeted therapy drug mainly used to treat non-small cell lung cancer (NSCLC), especially for patients with ALK gene rearrangements. It has significant efficacy.

From a pharmacokinetic perspective, brigatinib can be rapidly absorbed after oral administration, and the median time to reach peak plasma concentration (Tmax) is usually 1 to 3 hours after oral administration. This suggests that the drug works relatively quickly in the body. However, the duration of drug effect does not only depend on the absorption rate of the drug, but also is related to factors such as the drug's half-life, clearance rate, and individual differences.

Clinical studies have shown that brigatinib can delay disease progression and effectively shrink tumors in most patients. For example, in one study, about 70 to 80% of patients showed signs of tumor shrinkage after taking brigatinib. The duration of this effect varies from individual to individual, but usually lasts for several months or longer.

Brigatinib has also demonstrated the ability to penetrate the blood-brain barrier and has certain efficacy in treating brain metastases. This is particularly important for patients with advanced NSCLC, as brain metastasis is one of the common complications in these patients. Brigatinib can control disease progression and improve patients' quality of life.

It should be noted that although brigatinib has achieved remarkable results in the treatment of NSCLC, patients may also experience some adverse reactions during use, such as nausea, diarrhea, fatigue, etc. Therefore, you should follow the guidance of a professional physician when using brigatinib, and conduct regular physical examinations to monitor drug effects and side effects.

References:

https://pmc.ncbi.nlm.nih.gov/articles/PMC9438904/